Ellen Holm Nielsen
Corporate Officer/Principal bij University of Southern Denmark
Actieve functies van Ellen Holm Nielsen
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| University of Southern Denmark | Corporate Officer/Principal | - | - |
| University of California, Berkeley | Corporate Officer/Principal | - | - |
| Albert Einstein College of Medicine, Inc. | Corporate Officer/Principal | 14-08-2009 | - |
| University of Copenhagen | Corporate Officer/Principal | - | - |
Loopbaan van Ellen Holm Nielsen
Eerdere bekende functies van Ellen Holm Nielsen
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Profylakse ApS
 Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations. | Directeur/Bestuurslid | - | 22-11-2013 |
Statistieken
Internationaal
| Denemarken | 4 |
| Verenigde Staten | 3 |
Operationeel
| Corporate Officer/Principal | 4 |
| Director/Board Member | 1 |
Sectoraal
| Consumer Services | 5 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Profylakse ApS
Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations. | Health Technology |
- Beurs
- Insiders
- Ellen Holm Nielsen
- Ervaring
